Stoke Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.64B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 3, 2026 | After market close | $9.30M | $-0.93 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $6.20M | $-0.79 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | After market close | $10.60M | $-0.65 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | – | $-0.40 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | $158.57M | $1.90 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 18, 2025 | Before market open | $22.60M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | Before market open | $4.90M | $-0.47 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 6, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 25, 2024 | After market close | – | – | – |
Press releases
Announcements Stoke Therapeutics filed with the SEC
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Stoke Therapeutics Second Quarter 2025 Business Update Webcast for Investors & Analysts August 12, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment
Regulation FD disclosure · EX-99.1 to Form 8-K
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an
Regulation FD disclosure · EX-99.1 to Form 8-K
COPY YR RI IG GH HT T 2 20 02 25 5 | | S ST TOKE OKE T TH HER ERA AP PEU EUT TI ICS CS | | 1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Stoke Therapeutics Announces CEO Transition
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
& Phase 3 Plans Virtual Event for Investors & Analysts January 7, 2025 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE
Other events · EX-99.1 to Form 8-K
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001
Regulation FD disclosure · EX-99.1 to Form 8-K
Analysis of STK-001 for the Treatment
Regulation FD disclosure · EX-99.2 to Form 8-K
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Executive Officer nd 42 Annual J.P. Morgan Healthcare Conference January 10, 2024 © Copyr ©i g Ch op t 2024 yrightS 2024 toke T Sh tok era ep T e h u e tr ic as peutic1 s
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome
Regulation FD disclosure · EX-99.1 to Form 8-K
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with
Regulation FD disclosure · EX-99.1 to Form 8-K
Analysis of STK-001 for the Treatment
Regulation FD disclosure · EX-99.2 to Form 8-K
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
Results of operations · EX-99 to Form 8-K
Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Executive Officer st 41 Annual J.P. Morgan Healthcare Conference January 10, 2023 © Copy © Copy right 20 ri23 ght S20 toke 23 Therape Stoke Therape utics utic1 s
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a
Regulation FD disclosure · EX-99.1 to Form 8-K
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K